The stock of Transmedics Group Inc (NASDAQ: TMDX) has increased by 26.43 when compared to last closing price of 94.13. Despite this, the company has experienced a 33.90% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-01 that TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan – Gilmartin Group, Investor Relations Waleed Hassanein – President & Chief Executive Officer Stephen Gordon – Chief Financial Officer Conference Call Participants Allen Gong – JPMorgan Josh Jennings – TD Cowen Suraj Kalia – Oppenheimer & Company Operator Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
TMDX has 36-month beta value of 1.87. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TMDX is 31.48M, and currently, short sellers hold a 20.09% ratio of that float. The average trading volume of TMDX on May 01, 2024 was 772.29K shares.
TMDX’s Market Performance
The stock of Transmedics Group Inc (TMDX) has seen a 33.90% increase in the past week, with a 63.88% rise in the past month, and a 38.75% gain in the past quarter. The volatility ratio for the week is 4.84%, and the volatility levels for the past 30 days are at 6.41% for TMDX. The simple moving average for the past 20 days is 33.32% for TMDX’s stock, with a 63.89% simple moving average for the past 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with Piper Sandler repeating the rating for TMDX by listing it as a “Overweight.” The predicted price for TMDX in the upcoming period, according to Piper Sandler is $95 based on the research report published on March 28, 2024 of the current year 2024.
JP Morgan gave a rating of “Overweight” to TMDX, setting the target price at $48 in the report published on August 02nd of the previous year.
TMDX Trading at 42.48% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 19.45% of gains for the given period.
Volatility was left at 6.41%, however, over the last 30 days, the volatility rate increased by 4.84%, as shares surge +58.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.20% upper at present.
During the last 5 trading sessions, TMDX rose by +34.79%, which changed the moving average for the period of 200-days by +27.39% in comparison to the 20-day moving average, which settled at $91.49. In addition, Transmedics Group Inc saw 50.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Hassanein Waleed H, who sale 4,000 shares at the price of $95.12 back on Apr 17 ’24. After this action, Hassanein Waleed H now owns 74,087 shares of Transmedics Group Inc, valued at $380,480 using the latest closing price.
Hassanein Waleed H, the President & CEO of Transmedics Group Inc, sale 12,000 shares at $95.09 during a trade that took place back on Apr 10 ’24, which means that Hassanein Waleed H is holding 74,087 shares at $1,141,080 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.64 for the gross margin
The net margin for Transmedics Group Inc stands at -0.1. The total capital return value is set at -0.04. Equity return is now at value -15.42, with -5.09 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at 3.7. The interest coverage ratio of the stock is -2.66.
Currently, EBITDA for the company is 8.76 million with net debt to EBITDA at -7.11. When we switch over and look at the enterprise to sales, we see a ratio of 16.27. The receivables turnover for the company is 3.8for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
To put it simply, Transmedics Group Inc (TMDX) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
